Finanzen von SpringWorks Therapeutics Inc (SWTX)SWTXSpringWorks Therapeutics Inc

Evaluating the bottom line, SpringWorks Therapeutics Inc maintains a gross margin of 92.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -164.07%, while the net margin is -169.47%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SWTX converts its operational activities into shareholder value.

In the context of the broader market, SWTX competes directly with industry leaders such as RNA and ACLX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SWTX's gross margin of 92.81% stands against RNA's 100.00% and ACLX's 100.00%. Such benchmarking helps identify whether SpringWorks Therapeutics Inc is trading at a premium or discount relative to its financial performance.